Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the FDA
has provided notification that the Company has completed the necessary
preclinical toxicology testing in order to administer repeated doses of
CTP-354 in excess of 6 mg per day, lifting its partial clinical hold.
for Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity investment picks